👏
🚀 Orakl Oncology is thrilled to announce a seed round of €11 million to launch first-in-class AI-powered drug development products for biopharma and biotech ✨ We raised €11 million in seed funding, led by Singular. This investment follows a €3M pre-seed round in October 2023 led by Speedinvest with participation from HCVC and Verve Ventures. This funding will fuel the development of Orakl’s business unit and prepare the company for strategic collaborations with pharmaceutical partners. To lead this initiative, we have appointed Jessica Atkinson (FMI, Merck) as Business Advisor and opened a BD director position. We are now marketing our first AI-powered commercial solutions, the first product, O-Predict, forecasts patient responses to new drug candidates, predicting key clinical outcomes such as the number of responders and progression-free survival. 🔮 Our mission at Orakl is to revolutionize drug development by offering an unparalleled decision-making platform that empowers drug developers to de-risk clinical trials and expedite the availability of new transformative medicines. We aim to redefine the future of precision medicine and deliver breakthroughs that patients desperately need. 🙏 We warmly thank our investors and business angels for their continuous support in this mission, as well as Gustave Roussy, our other partners, and our Oraklees for their tremendous contributions. We will be recruiting, stay posted! SISTAFUND, Tatiana Jama Natacha Brami, Jonathan Benhamou, Sébastien Bazin, Paul Bazin, Maximilien Levesque, Mostafa ElSayed, François Morice, Bpifrance Thanks to Les Echos and TechCrunch for their articles about Orakl Oncology, you will find the links in the comment section. cc Fanny Jaulin, PhD, Diane-Laure Pagès, Gustave Ronteix, Jeremy Uzan, Maud Larbey, Andrea Zitna, Estelle Botbol 🎗️, Alexis Houssou, Xavier Mesnier, Fabrice Barlesi, Christophe Javaud